Table 2.

Other Recommended Initial Antiretroviral Therapy (ART) Regimens^a

Regimensb	Potential uses and cautions
• Darunavir/cobicistat/tenofoviralafenamide/emtricitabinec • Darunavir/cobicistat plus tenofovir disoproxil fumarate/lamivudined	• Potential use for patients with known or suspected pretherapy multidrug resistance • Potential use for patients who have resistance to InSTIs • Potential use for patients at high risk of poor adherencee
• Dolutegravir/abacavir/lamivudine	• Caution for patients with kidney insufficiencyf
• Doravirine/tenofovir disoproxil fumarate/lamivudinec • Doravirine plus tenofovir alafenamide/emtricitabine • Doravirine plus tenofovir disoproxil fumarate/lamividinec	• Potential use for patients who are intolerant to InSTIs
• Efavirenz (400 mg or 600 mg) plus tenofovir disoproxil fumarate/lamivudinec,d • Efavirenz (400 mg or 600 mg) plus tenofovir disoproxil fumarate/emtricitabine	• Potential use for patients being treated for co-infection with HIV and tuberculosis • Potential use for patients who are pregnant or intend to become pregnant
• Raltegravir plus tenofoviralafenamide/emtricitabine • Raltegravir plus tenofovir disoproxilfumarate/emtricitabine • Raltegravir plus tenofovir disoproxil fumarate/lamivudined	• Potential use for patients at high risk of drug-drug interactions • Potential use for patients who are intolerant to other InSTI initial regimens • Potential use for patients with child-bearing potential who are trying to conceive • Potential use for patients who are sexually active and not consistently using contraception
• Rilpivirine/tenofovir alafenamide/emtricitabinec,g • Rilpivirine plus tenofovir disoproxil fumarate/lamivudined,g	• Potential use for patients who are intolerant to InSTIs • Small pill size is an advantage for some patients

Abbreviation: InSTI, integrase strand transfer inhibitor.

^aThe recommended initial ART regimens appear in Box 2.

^bThe regimens are listed in alphabetical order. Drug components separated with a virgule indicate these are available as co-formulations.

^cAvailable as a single-tablet co-formulation.

^dAvailable in generic formulations in many countries.

^eDarunavir has a high barrierto resistance.

^fFixed-dosecombination should not be used ifcreatinineclearance rate is below 50 mL/min.

^gUse this regimen only if pretreatment HIV RNA level is below100 000 copies/mL and CD4cell count is 200/μL.